

## Albion Development VCT PLC Interim Management Statement

### Introduction

I am pleased to present Albion Development VCT PLC's interim management statement for the period from 1 January to 18 May 2011 as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3.

### Performance and dividends

The Company's Ordinary shares' unaudited net asset value (NAV), based on management accounts, as at 31 March 2011 was £22.7 million (31 December 2010: £21.2 million) or 73.7 pence per share (excluding treasury shares) (31 December 2010: 72.9 pence per share).

The Company's D shares' unaudited net asset value (NAV), based on management accounts, as at 31 March 2011 was £5.8 million (31 December 2010: £5.9 million) or 91.5 pence per share (excluding treasury shares) (31 December 2010: 91.8 pence per share).

The current NAVs and comparative figures are calculated after accounting for the first dividend for the year to 31 December 2011 of 2.5 pence per Ordinary share (total cost: £771,000) and 1.25 pence per D share (total cost £79,000) which will be paid on 31 May 2011 to shareholders on the register as at 3 May 2011.

On this basis, the Company's Ordinary shares' net asset value has risen by 0.8 pence per share or 1 per cent. since 31 December 2010 as a result of an increase in the Ordinary shares' investment valuations, and the D shares' net asset value has reduced slightly as a result of the costs of the business.

### Portfolio

The following investments have been made during the period from 1 January 2011 to 18 May 2011:

Name	£000's	
The Street by Street Solar Programme Limited ( <i>new investment</i> )	417	<i>Photo-voltaic installations on domestic roofs in Maidenhead &amp; Windsor</i>
Nelson House Hospital Limited ( <i>new investment</i> )	396	<i>Psychiatric hospital in Gosport, Hampshire.</i>
Masters Pharmaceuticals Limited ( <i>further investment</i> )	148	<i>International specialist distribution of pharmaceuticals</i>
Abcodia Limited ( <i>new investment</i> )	135	<i>Biomarker licensing business</i>
Regenerco Renewable Energy Limited ( <i>new investment</i> )	130	<i>Photo-voltaic installations on commercial buildings</i>
AVESI Limited ( <i>new investment</i> )	104	<i>Photo-voltaic installations on small commercial buildings</i>
Prime Care Holdings Limited ( <i>further investment</i> )	43	<i>Domiciliary care services</i>
Helveta Limited ( <i>further investment</i> )	30	<i>Timber and food tracing software</i>
Opta Sports Data Limited ( <i>further investment</i> )	25	<i>Leading sports data management company</i>
Xceleron Limited ( <i>further investment</i> )	25	<i>Provider of a range of drug development services to the life science industry</i>

### Disposals

During the period from 1 January 2011 to 18 May 2011, the following loan stock repayments were made:

Name	£000's
Peakdale Molecular Limited	28
CS (Greenwich) Limited	46

**Top ten qualifying holdings as at 31 March 2011:**

<b>Investment</b>	<b>Carrying value £000's</b>
Evolutions Group Limited	2,383
Radnor House School Limited	1,565
Weybridge Health Club Limited	1,233
Blackbay Limited	1,155
C S (Greenwich) Limited	952
Dexela Limited	870
Peakdale Molecular Limited	858
Kensington Health Clubs Limited	774
Masters Pharmaceuticals Limited	693
Taunton Hospital Limited	576

**Albion VCTs Linked Top Up Offer**

On 6 April 2011, the Company announced that the Albion VCTs Linked Top Up Offer would be extended to 16 May 2011 for applications in respect of the tax year to 5 April 2012. The Offer has now closed.

During the period from 1 January to 31 March 2011, the Company issued the following Ordinary shares under the Albion VCTs Linked Top Up Offer:

<b>Date</b>	<b>Number of Ordinary shares issued</b>	<b>Issue price (per share including 5% costs of issue)</b>	<b>Net proceeds £'000</b>
7 January 2011	816,370	80.1	604
22 March 2011	811,163	80.1	614

These amounts have been included in the management accounts figures disclosed above.

In addition, since 31 March 2011, the following shares were issued under the Top Up Offer:

<b>Date</b>	<b>Number of Ordinary shares issued</b>	<b>Issue price (per share including 5% costs of issue)</b>	<b>Net proceeds £'000</b>
5 April 2011	533,103	80.1	400
16 May 2011	47,058	77.1	34

**Material Events and Transactions**

During the period from 1 January 2011 to 31 March 2011, the Company did not purchase any of its own shares. Since 31 March 2011, the Company has purchased 412,372 Ordinary shares for cancellation at an average price of 62.7 pence per Ordinary share.

The Company continues to offer a Dividend Reinvestment Scheme to existing shareholders. Details of this Scheme can be found at [www.albion-ventures.co.uk/Our Funds/Albion Development VCT PLC](http://www.albion-ventures.co.uk/Our_Funds/Albion_Development_VCT_PLC).

There have been no further significant events or transactions that the Board is aware of which would have a material impact on the financial position of the Company between 1 January 2011 and 18 May 2011.

Further information regarding historic and current financial performance and other useful shareholder information can be found on the Fund's website under [www.albion-ventures.co.uk/Our Funds/Albion Development VCT PLC](http://www.albion-ventures.co.uk/Our_Funds/Albion_Development_VCT_PLC).

Geoffrey Vero, Chairman  
19 May 2011

For further information please contact:

Patrick Reeve, Albion Ventures LLP – tel: 020 7601 1850